Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →CareDx has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170 million. The…
This divestiture allows us to strategically focus on our core Testing Services and Patient and Digital Solutions, where our solutions-selling strategy is…
This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation, said Denis Fortier, CEO of Eurobio Scientific.…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
CareDx (CDNA) entered a definitive agreement to divest its Lab Products business to Eurobio Scientific for $170M in cash, sharpening focus on its Testing Services and Patient & Digital Solutions businesses.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eurobio Scientific / CareDx Lab Products business (this deal) | 2026 | $170M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2026 deals · Other deals